Protective effect of insulin against hypoglycemia-associated counterregulatory failure

B Fruehwald-Schultes1, W Kern, E Deininger

  • 1Department of Internal Medicine I, University of Luebeck, Germany. fruehwal@kfg.mu-luebeck.de

Insights

Previous hypoglycemia impairs the body's response to low blood sugar. Insulin offers some protection against this impaired counterregulation, highlighting its role in glucose homeostasis.

Area of Science:

  • Endocrinology
  • Metabolic Regulation
  • Neuroscience

Background:

  • Recurrent hypoglycemia can blunt the body's counterregulatory response.
  • The specific role of insulin in this blunting effect remains unclear.

Purpose of the Study:

  • To investigate the impact of antecedent hypoglycemia with varying insulin levels on subsequent counterregulatory responses.
  • To elucidate insulin's role in mitigating the effects of prior hypoglycemia on glucose regulation.

Main Methods:

  • Healthy men underwent antecedent hypoglycemic clamps with low (1.5 mU/min x kg) or high (15.0 mU/min x kg) insulin infusion.
  • Subsequent stepwise hypoglycemic clamps were performed the next day.
  • Counterregulatory hormone levels (ACTH, cortisol, norepinephrine, glucagon) were measured and compared to a control group without antecedent hypoglycemia.

Main Results:

  • Low insulin antecedent hypoglycemia significantly blunted ACTH, cortisol, and norepinephrine responses compared to controls.
  • High insulin antecedent hypoglycemia did not significantly blunt these counterregulatory responses.
  • Cortisol, norepinephrine, and glucagon responses were greater following high insulin antecedent hypoglycemia than low insulin antecedent hypoglycemia.

Conclusions:

  • A single episode of mild hypoglycemia impairs neuroendocrine counterregulation 18-24 hours later.
  • Insulin exerts a moderate protective effect against the blunting of subsequent counterregulatory responses to hypoglycemia.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...